Previous 10 | Next 10 |
2024-05-28 00:08:10 ET Summary FibroGen focuses on developing Pamrevlumab for pancreatic cancer therapy after disappointing trial results for other indications. If successful, Pamrevlumab’s phase 3 trials in pancreatic cancer could be a major value driver. Roxadustat ha...
FG-3246 and enzalutamide combination therapy led to a median radiographic progression free survival (rPFS) of 10.2 months in biomarker unselected patients FG-3246 demonstrated an acceptable safety profile; adverse events consistent with those observed in other antibody drug conjugat...
2024-05-07 11:35:38 ET A California-based %Biotech company is stealing the show so far during Tuesday’s session after the company reported Q1 2024 earnings after yesterday’s market close. According to a handful of press releases, the company beat EPS estimates by $0.22...
2024-05-07 10:01:47 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 16 out...
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company’s management will participate in the following investor conferences: Bank of America Health Care Conference Format: 1x1 investor meetings Date: Tuesday, May 14,...
2024-05-06 22:31:06 ET FibroGen, Inc. (FGEN) Q1 2024 Earnings Conference Call May 6, 2024 05:00 PM ET Company Participants David DeLucia - VP, Corporate FP&A and IR Thane Wettig - CEO Deyaa Adib - CMO Juan Graham - CFO Chris Chung - SVP, China Operati...
2024-05-06 16:07:17 ET More on FibroGen FibroGen, Inc. 2023 Q4 - Results - Earnings Call Presentation FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript FibroGen falls after early-stage data for prostate cancer drug AstraZeneca returns right to roxadustat...
Topline data from the Pancreatic Cancer Action Network (PanCAN) Precision Promise SM Phase 2/3 study in metastatic pancreatic cancer anticipated in mid-2024 Topline data from LAPIS Phase 3 study in locally advanced unresectable pancreatic cancer anticipated in ...
PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....
2024-05-03 17:20:20 ET More on FibroGen FibroGen, Inc. 2023 Q4 - Results - Earnings Call Presentation FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript FibroGen falls after early-stage data for prostate cancer drug AstraZeneca returns right to roxadustat...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...